Machine Learning for Warfarin Therapy: A Systematic Review

机器学习在华法林治疗中的应用:系统性综述

阅读:1

Abstract

Background: Despite the availability of direct oral anticoagulants, warfarin remains essential for mechanical valves, renal impairment, and resource-limited settings. Traditional dosing achieves therapeutic range in only 55-65% of patients, increasing bleeding and thrombotic complications. This systematic review evaluates the literature on machine learning (ML) approaches for warfarin dose prediction (2022-2025). Methods: We analysed 14 studies encompassing 122,400 patients across nine countries following PRISMA guidelines. Studies utilizing ML algorithms for warfarin dosing with quantifiable performance metrics were included. Risk of bias was assessed using PROBAST. Results: Reinforcement learning demonstrated superior performance, achieving an 80.8% excellent responder ratio versus 41.6% for standard practice and 99.5% safety responder ratio versus 83.1%. Support vector machines achieved R(2) up to 0.98 in homogeneous populations. Mean absolute error ranged from 0.11 to 1.8 mg/day, consistently outperforming traditional methods. Seven studies included external validation, whilst 78.6% were retrospective designs. Limited implementation studies showed therapeutic INR rates improving from 47.5% to 61.1%. Critically, only three studies (21.4%) reported any safety outcomes, with none adequately powered to detect differences in major bleeding events. Conclusions: While ML algorithms demonstrate improved dosing accuracy in retrospective analyses, the near-complete absence of adequately powered safety outcome data represents the primary barrier to clinical implementation. Without robust evidence on bleeding, thromboembolism, and mortality, the risk-benefit profile remains unknown. Implementation requires addressing: the predominance of retrospective studies (78.6%), limited prospective validation, restricted geographic diversity (43% from China), absence of African and South American studies, and no new Hispanic population data. Multicentre prospective trials with safety endpoints, population-specific validation, and interpretable models are essential before widespread clinical adoption can be recommended.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。